This week’s China healthcare highlights include METiS Therapeutics clearing its HKEX IPO hearing under Chapter 18C as the first AI-driven drug delivery company, leveraging its NanoForge platform and lead drug MTS-004 targeting pseudobulbar affect. TJ Biopharma signed a US$ 850M deal granting Biogen exclusive rights to felzartamab in Greater China for kidney diseases. QL Biopharmaceuticals filed for a Hong Kong IPO to advance ZT002, a GLP-1 receptor agonist in Phase III for obesity. IMPACT Therapeutics and InxMed also moved forward with their HKEX IPOs, focused on precision oncology and synthetic lethality. At AACR 2026, Hansoh announced strong Phase 1 results for its fourth-gen EGFR inhibitor HS-10504 in NSCLC, while Hengrui and Akeso reported positive outcomes for HER2-mutant NSCLC and pancreatic cancer, respectively. Other notable updates include Merck’s bispecific antibody MK-2010 in NSCLC and GeneScience’s innovative oncology pipeline featuring ADCs and TCEs, highlighting active innovation across China’s biotech landscape.

Transactions

METiS Therapeutics Clears Hearing for HKEX IPO as AI Drug Delivery Pioneer

Key Words: METiS, HKEX, IPO, AI drug delivery, NanoForge, MTS-004, pseudobulbar affect, nanomaterials, mRNA, bispecific antibodies, Chapter 18C

• The News: On April 26, 2026, METiS successfully passed its listing hearing and is preparing for an initial public offering (IPO) on the Hong Kong Stock Exchange (HKEX) under the Chapter 18C rules, targeting to become the first AI-driven drug delivery company to go public in Hong Kong. The IPO is jointly sponsored by Jefferies, Deutsche Securities Asia, and CITIC Securities.
• Key Highlights:
• AI Platform – NanoForge: METiS has developed a proprietary NanoForge platform that leverages AI models, a vast lipid library, and high-throughput experimental systems to design and optimize nanomaterial-based drug delivery systems for macromolecular drugs (e.g., nucleic acids and proteins).
• Pipeline:
  • MTS-004: Lead program targeting pseudobulbar affect (PBA), currently completing Phase III clinical trials.
  • MTS-105: A preclinical candidate designed to deliver mRNA-encoded bispecific antibodies (BsAbs) directly to the liver for cancer treatment.
• Licensing and Partnerships:
  • Recent licensing deal for MTS-004 valued at up to RMB 1.8 billion (US$ 265 million).
  • Business model includes platform partnerships with pharmaceutical companies and product licensing.

Biogen (BIIB.O) Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region

Key Words: TJ Biopharma, Biogen, felzartamab, CD38, monoclonal antibody, Greater China, licensing deal, multiple myeloma, immune-mediated kidney diseases

• The News: On April 21, 2026, China-based TJ Biopharma announced a definitive agreement with Biogen, granting Biogen exclusive rights to felzartamab in Greater China, which includes Mainland China, Hong Kong, Macau, and Taiwan. The deal is valued at up to US$ 850 million, comprising a US$ 100 million upfront payment and up to US$ 750 million in potential milestone payments, along with tiered royalties. This agreement consolidates global rights to felzartamab under Biogen, which previously obtained the ex-Greater China rights in July 2024 via its acquisition of Human Immunology Biosciences (HI-Bio).
• Key Highlights:
• Felzartamab Overview: An investigational anti-CD38 monoclonal antibody (mAb) currently in Phase III clinical development for multiple immune-mediated kidney diseases, including antibody-mediated rejection, IgA nephropathy (IgAN), and primary membranous nephropathy (PMN).
• China Submission: TJ Biopharma has separately submitted a biologics license application (BLA) for felzartamab in China for the treatment of multiple myeloma (MM), which is under regulatory review.
• Deal Structure:
  • Total deal value: Up to US$ 850 million.
  • Upfront payment: US$ 100 million.
  • Milestone payments: Up to US$ 750 million.
  • Additional tiered royalties on net sales.
• Development and Manufacturing: Biogen will oversee the development, production, and commercialization of felzartamab for immunology indications in Greater China, while TJ Biopharma will act as the manufacturer.

QL Biopharmaceuticals Files for Hong Kong IPO, Raising Total RMB 1.1 Billion to Date

Key Words: QL Biopharmaceuticals, Hong Kong IPO, GLP-1, ZT002, ZT006, obesity, type 2 diabetes, MASH, metabolic disease

• The News: On April 24, 2026, QL Biopharmaceuticals, a China-based biopharmaceutical company, filed for an initial public offering (IPO) on the Hong Kong Stock Exchange. Founded in 2018, the company focuses on developing next-generation therapies for metabolic diseases, including obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH).
• Key Highlights:
• Core Product – ZT002: A once-monthly GLP-1 receptor agonist, ZT002 is QL’s lead asset currently in Phase III clinical trials in China for weight loss.
• Phase II Data: Demonstrated a 13.8% average weight reduction after 24 weeks (160 mg, once every 4 weeks), outperforming semaglutide (2.4 mg, weekly) and matching other once-monthly candidates in efficacy. 97.1% of participants achieved at least 5% weight loss without reaching a plateau.
• Pipeline:
  • ZT006: An oral GLP-1 peptide showing weight loss potential in Phase II trials, with low double-digit percentage reductions in body weight after 6 weeks of treatment.
  • ZT003: A GLP-1/FGF21 dual agonist for MASH and severe hypertriglyceridemia (SHTG) currently in Phase I trials.
  • Additional preclinical candidates include ZT010 (monthly Amylin), ZT012 (oral Amylin), and ZT011/ZT013 (GLP-1/GIP/GLP multiple agonists).
• Financials:
  • Total funding to date: RMB 1.1 billion.
  • 2025 net loss: RMB 191 million.
  • Cash reserves: RMB 31.2 million.
• The funds raised from the IPO will primarily be allocated to advancing the late-stage clinical trials, regulatory approval, and commercialization of the company’s lead candidate, ZT002. Additionally, proceeds will support the clinical development of key pipeline programs, such as ZT006 and ZT003, and enhance QL Biopharmaceuticals’ internal production capabilities. A portion of the capital will also be reserved for working capital and general corporate purposes.

IMPACT Therapeutics Clears HKEX Listing Hearing

Key Words: IMPACT Therapeutics, Hong Kong IPO, synthetic lethality, PARP inhibitors, senaparib, ADCs, protein degraders

• The News: On April 20, 2026, IMPACT Therapeutics, Inc., headquartered in Shanghai and registered in Nanjing, released its post-hearing information pack for an upcoming initial public offering (IPO) on the Hong Kong Stock Exchange (HKEX). The company, which initially filed in September 2025 and resubmitted in March 2026, is expected to list soon on the Main Board.
• Key Highlights:
• Founded in 2009, IMPACT Therapeutics is a commercial-stage biotech company focused on advancing precision oncology therapies based on synthetic lethality. The company is one of only three globally with both a commercial-stage PARP1/2 inhibitor and a clinical-stage next-generation PARP1-selective inhibitor.
• Core Product – Senaparib: A PARP1/2 inhibitor approved in China for first-line maintenance therapy in ovarian cancer, regardless of mutation status. Senaparib has demonstrated best-in-class clinical profiles.
• Pipeline:
  • The company’s pipeline includes one approved drug, four clinical-stage assets, and seven preclinical candidates targeting synthetic lethality pathways such as PARP1/2, PARP1, ATR, WEE1, PKMYT1/WEE1, DHX9, ATM, USP1, and CHK1/2.
  • Emerging therapies include next-generation antibody-drug conjugates (ADCs) and protein degraders.
• Financials:
  • Revenue: RMB 33.5 million in 2024 and RMB 38.3 million in 2025.
  • R&D Expenses: RMB 195 million in 2024 and RMB 184 million in 2025.
  • Net Loss: RMB 255 million in 2024 and RMB 296 million in 2025.

InxMed Files for Hong Kong IPO with FAK Inhibitor in Phase III

Key Words: InxMed, Hong Kong IPO, FAK inhibitor, ifebemtinib, synthetic lethality, tumor resistance, ADC, biotech financing

• The News: On April 21, 2026, InxMed Limited submitted its latest application for an initial public offering (IPO) on the Main Board of the Hong Kong Stock Exchange (HKEX). The IPO is jointly sponsored by CITIC Securities and CCB International. InxMed focuses on addressing tumor resistance, with its core product ifebemtinib (IN10018) being the only highly selective FAK inhibitor in Phase III clinical trials in China.
• Key Highlights:
• Core Product – Ifebemtinib (IN10018):
  • Ifebemtinib is an oral FAK (focal adhesion kinase) inhibitor that targets tumor resistance by improving the tumor microenvironment, enhancing drug penetration, and increasing tumor cell sensitivity to combination therapies.
  • Currently in Phase III clinical trials for platinum-resistant ovarian cancer, with the New Drug Application (NDA) submission expected in late 2026.
  • The drug has received three Breakthrough Therapy designations from China’s NMPA and one Fast Track designation from the FDA.
• Pipeline:
  • The company’s pipeline includes IN10028, a next-generation FAK inhibitor in Phase I trials, three antibody-drug conjugates (ADCs) targeting solid tumors, and a PD-1/GDF15 bispecific antibody expected to enter clinical trials in late 2026.
  • These programs build on InxMed’s strategy of focusing on combination therapies rather than monotherapies to address tumor resistance.
• Financing and Market Position:
  • InxMed has raised approximately RMB 929 million across six financing rounds, including key investments from strategic and institutional investors such as SDIC Venture Capital and Fosun.
  • In August 2025, the company raised US$ 33.7 million in a Series C financing round, setting its post-money valuation at US$ 306 million.
  • Ifebemtinib’s market potential is strong, with industry data projecting the global FAK inhibitor market to reach US$ 5.14 billion by 2035 with a compound annual growth rate (CAGR) of 65.0% (2026–2035).
• Proceeds from the IPO will be used to advance ifebemtinib to completion of Phase III trials and regulatory approval, expand early-stage pipeline projects, and prepare for commercialization. Remaining funds will support general corporate purposes.

Tortugas Neuroscience Launches with US$ 106M to Develop Four Phase 2 Neurology Drugs Licensed from Asia

Key Words: Tortugas Neuroscience, Eisai, Hansoh Pharmaceutical, TRTL-107, GABA receptor, GAT-1 inhibitor, PDE9 inhibitor, schizophrenia, tinnitus, epilepsy, reversible encephalopathies, neurology startup, Phase 2 trials

• The News: On April 21, 2026, Tortugas Neuroscience, a newly launched neurology-focused biotech founded by two Sage Therapeutics veterans, announced its debut with US$ 106 million in funding and a clinical-stage pipeline of four Phase 2 drug candidates licensed from Eisai and Hansoh Pharmaceutical. The company, based in Framingham, Massachusetts, is developing small molecules with “derisked mechanisms of action” for large and well-defined neurology indications.
• Key Highlights:
• Hansoh Assets: Tortugas licensed two compounds from China-based Hansoh Pharmaceutical:
  • TRTL-107, a D2/D3 partial agonist and 5-HT2A antagonist in Phase 2 development for schizophrenia.
  • A GABA receptor-positive allosteric modulator being developed for tinnitus.
• Eisai Assets: The company also secured two compounds from Japan’s Eisai:
  • A GAT-1 inhibitor for focal epilepsy.
  • A PDE9 inhibitor for reversible encephalopathies.
• Development Priorities: Tortugas plans to use this funding to complete Phase 2 trials for its schizophrenia and tinnitus programs. The company aims to develop oral, once-daily therapies with clear regulatory paths to approval.
• Tortugas was founded with strong financial support from Cure Ventures, The Column Group, and AN Venture Partners. The US$ 106 million includes seed and Series A funding rounds co-led by Cure Ventures.

Clinical

Phanes Therapeutics Announces Positive Phase I/II Data for Claudin 18.2/CD47 Bispecific Antibody at AACR 2026

Key Words: Phanes Therapeutics, spevatamig, claudin 18.2/CD47 bispecific antibody, AACR 2026, pancreatic cancer, combination therapy

• The News: Phanes Therapeutics, Inc. reported positive Phase I/II clinical data for spevatamig, a claudin 18.2/CD47 bispecific antibody, at the AACR 2026 Annual Meeting. The data highlights spevatamig’s safety, tolerability, and pharmacokinetic profile, reinforcing its potential as a combination therapy for advanced cancers.
• Key Highlights:
• Safety and Tolerability: Spevatamig demonstrated effective regulation of CD47 at therapeutic doses, mitigating hematologic toxicity while exhibiting minimal gastrointestinal toxicity associated with claudin 18.2 targeting.
• Pharmacokinetics: Dose-proportional drug exposure was confirmed, with no observed interaction when co-administered with gemcitabine plus nab-paclitaxel (GnP). This supports seamless combination therapy dosing.
• Therapeutic Potential: The data support the use of spevatamig in combination with GnP for first-line treatment of pancreatic cancer.

Hansoh Pharma (3692.HK) Reports Positive Phase 1 Results for Fourth-Generation EGFR Inhibitor HS-10504 in NSCLC at AACR 2026

Key Words: Hansoh Pharma, HS-10504, EGFR inhibitor, NSCLC, C797S mutation, AACR 2026

• The News: Hansoh Pharmaceutical announced positive results from a Phase 1 study of HS-10504, its fourth-generation EGFR inhibitor, in advanced non-small cell lung cancer (NSCLC) patients with EGFR C797S mutations. The data was presented at the AACR 2026 Annual Meeting.
• Key Highlights:
• Efficacy: The study demonstrated an objective response rate (ORR) of 52.9% and median progression-free survival (mPFS) of 9.6 months at the recommended Phase 2 dose (RP2D) of 400 mg once daily.
• Safety: HS-10504 showed a manageable safety profile, with most treatment-related adverse events (TRAEs) being grade 1-2 in severity.
• HS-10504 is a novel, highly selective fourth-generation EGFR tyrosine kinase inhibitor (TKI) specifically designed to target resistance mutations, including EGFR C797S.

GeneScience Pharmaceuticals (000661.SZ) Highlights Innovative Oncology Pipeline at AACR 2026

Key Words: GeneScience, ADC, TCE, GenSci139, GenSci140, GenSci145, AACR 2026

• The News: GeneScience Pharmaceuticals showcased its latest oncology pipeline at the AACR 2026 Annual Meeting, featuring multiple innovative assets, including bispecific antibody-drug conjugates (BsADCs), small molecule inhibitors, and trispecific T-cell engagers (TCEs). Among these, several assets demonstrated “Best-in-Class” potential in preclinical and early clinical studies.
• Key Projects:
• GenSci139 (EGFR x HER2 Bispecific ADC): Designed to target both EGFR and HER2, GenSci139 employs GeneScience’s proprietary HydroLock™ technology, enhancing tumor targeting and internalization efficiency while improving the safety and stability of the payload. Preclinical studies confirmed significant anti-tumor activity across various solid tumor models, including bladder cancer, lung cancer, and gastric cancer.
• GenSci140 (FRα Bispecific ADC): GenSci140 targets folate receptor alpha (FRα) with dual epitope binding, demonstrating robust anti-tumor efficacy in ovarian cancer models irrespective of FRα expression levels. Currently in early clinical trials for advanced solid tumors, it aims to address unmet needs in platinum-resistant ovarian cancer.
• GenSci180 (CDH17 x CEACAM5 Bispecific ADC): Targeting colorectal cancer, GenSci180 combines two highly expressed tumor-associated antigens with superior binding affinity and enhanced cytotoxic activity. Preclinical data indicate significant tumor growth suppression and potential to overcome treatment limitations in late-stage colorectal cancer, with IND-enabling studies ongoing.
• GS24-B057 (Nectin-4 x Trop-2 Bispecific ADC): This dual-target ADC demonstrated strong efficacy and a manageable safety profile in multiple models, including triple-negative breast cancer, non-small cell lung cancer, and urothelial carcinoma.
• GenSci145 (Selective PI3Kα Mutation Inhibitor): A second-generation PI3Kα inhibitor specifically targeting mutant PI3Kα. Preclinical studies revealed potent anti-tumor activity with minimal metabolic side effects, as well as excellent blood-brain barrier penetration, supporting its potential against brain metastases. Phase I clinical trials are currently underway in China.
• GS24-B047 (DLL3 x CD3 x CD2 TCE): A trispecific T-cell engager targeting DLL3-expressing tumors, GS24-B047 connects tumor cells and T cells, enhancing cytotoxicity while reducing cytokine release. Preclinical studies showed excellent anti-tumor efficacy in small cell lung cancer (SCLC) and manageable safety profiles in primate studies.
• All ADC and TCE assets leverage GeneScience’s proprietary technologies, including HydroLock™, to enhance tumor selectivity, reduce toxicity, and improve overall therapeutic profiles.
• GeneScience plans to advance several programs into clinical development, including IND submissions for GenSci180 and GS24-B057, while continuing Phase I trials for GenSci145 and GS24-B047.

Hengrui (1276.HK, 600276.SS) Announces Positive Phase II Results for Trastuzumab Rezetecan in HER2-Mutant NSCLC at AACR 2026

Key Words: Jiangsu Hengrui, trastuzumab rezetecan, adebrelimab, HER2-mutant NSCLC, AACR 2026, Phase II

• The News: Hengrui Pharmaceuticals presented results from a Phase II clinical study of trastuzumab rezetecan, administered as monotherapy or in combination with adebrelimab, in untreated HER2-mutant advanced non-small cell lung cancer (NSCLC) patients, at the AACR 2026 Annual Meeting.
• Key Highlights:
• Study Design:
  • This randomized Phase II trial evaluated trastuzumab rezetecan monotherapy (4.8 mg/kg Q3W) or in combination with adebrelimab (anti-PD-L1, 1200 mg Q3W).
  • Patients enrolled were advanced NSCLC cases with HER2 mutations, receiving the treatments in the first-line setting.
• Efficacy Results:
  • The combination therapy achieved an Objective Response Rate (ORR) of 69.4% (95% CI: 51.9–83.7), a Disease Control Rate (DCR) of 91.7%, and the median Progression-Free Survival (PFS) was not reached at a median follow-up of 16.7 months.
  • The monotherapy achieved an Objective Response Rate (ORR) of 81.3% (95% CI: 63.6–92.8), a Disease Control Rate (DCR) of 93.8%, and a median Progression-Free Survival (PFS) of 17.9 months, showing a consistent trend of durable benefit.
• Safety Profile:
  • Both treatment regimens demonstrated good tolerability.
  • No new safety signals were observed, consolidating the manageable safety profiles of the

Guangzhou Lupeng Presents Encouraging Phase 1 Data for LP-118 in SCLC at AACR 2026

Key Words: Guangzhou Lupeng, LP-118, Bcl-2/Bcl-xL inhibitor, SCLC, AACR 2026, Phase 1

• The News: Guangzhou Lupeng Pharmaceutical announced initial Phase 1 clinical data for LP-118, an oral Bcl-2/Bcl-xL dual inhibitor, in patients with solid tumors, including small cell lung cancer (SCLC), at the AACR 2026 Annual Meeting.
• Key Highlights:
• Efficacy:
  • In 32 evaluable SCLC patients receiving ≥300 mg once daily, the objective response rate (ORR) was 15.6%, and the disease control rate (DCR) was 71.9%.
  • The median overall survival (OS) was 8.2 months.
• Safety and Tolerability:
  • LP-118 demonstrated a favorable safety profile.
  • The overall incidence of thrombocytopenia was low at 15.4%.

Junshi Biosciences (1877.HK) Presents Promising Clinical Data for JS212 and JS207 at AACR 2026

Key Words: Shanghai Junshi, JS212, JS207, EGFR×HER3 ADC, mCRC, HCC, AACR 2026

• The News: Junshi Biosciences presented clinical data from its innovative oncology programs JS212 and JS207 at the 2026 AACR Annual Meeting. The preliminary results highlight the clinical potential of these therapies in advanced solid tumors, MSS/pMMR metastatic colorectal cancer (mCRC), and advanced hepatocellular carcinoma (HCC).
• Key Highlights:
• JS212: FIH Study Results in Advanced Solid Tumors
  • Efficacy:
    • In 57 evaluable patients, JS212 achieved an ORR of 33.3% and a DCR of 93.0%.
    • At doses of 4.2 mg/kg and 4.6 mg/kg, ORRs were 44.4% and 50.0%, with 100.0% DCR in both groups.
    • High ORRs were observed in HER2-negative breast cancer (50.0%) and esophageal squamous cell carcinoma (38.9%).
  • Safety and Tolerability: JS212 was well-tolerated, with no maximum tolerated dose (MTD) reached.
• JS207: Phase II Study in MSS/pMMR mCRC
  • Efficacy:
    • Among 31 evaluable patients treated with JS207 combined with XELOX chemotherapy, the ORR was 71.0% and the DCR was 96.8%.
    • Median PFS and DoR were not yet mature due to limited follow-up.
  • Safety and Tolerability:
    • Grade ≥3 treatment-related adverse events (TRAEs) were reported in 40.6% of patients.
    • Immune-related adverse events (irAEs) ≥ Grade 3 occurred in only 3.1% of patients, with no treatment-related deaths.
  • JS207 + JS007: Phase II Study Results in Advanced HCC
    • Efficacy: The combination therapy demonstrated an ORR of 45.5%, showcasing strong anti-tumor synergy in advanced HCC.
    • Safety and Tolerability:
      • Common treatment-emergent adverse events (TEAEs) included elevated aspartate aminotransferase (53.8%) and fever (46.2%).
      • Grade ≥3 TRAEs occurred in 19.2% of patients, with good overall tolerability.

Merck & Co (NYSE: MRK) Unveils First Clinical Data for MK-2010, the Anti-PD-1 x VEGF Antibody Licensed from LaNova

Key Words: Merck, LaNova, MK-2010, AACR 2026, anti-PD-1 x VEGF, bispecific antibody, NSCLC

• The News: Merck & Co. has revealed the first clinical data for MK-2010, its anti-PD-1 x VEGF bispecific antibody, licensed from LaNova Medicines for US$ 588 million upfront in late 2024. Presented at AACR 2026, the results suggest promising antitumor activity and a manageable safety profile in non-small cell lung cancer (NSCLC).
• Key Highlights:
• Study Design and Patient Characteristics:
  • A total of 112 patients received treatment, including 40 in the dose-escalation cohort and 72 in the NSCLC expansion cohort.
  • The NSCLC cohort consisted of heavily pretreated patients:
    • 68% had prior systemic therapy.
    • 60% had prior anti-PD-(L)1 therapy.
    • 26% had prior anti-VEGF therapy.
  • Efficacy Results among treatment-naïve patients in the NSCLC expansion cohort:
    • 20 mg/kg Q3W: Unconfirmed overall response rate (ORR) of 55%.
    • 30 mg/kg Q3W: Unconfirmed ORR of 44%.
  • Safety Profile:
    • No grade 5 treatment-related adverse events (TRAEs) observed.
    • TRAEs in the NSCLC cohort were largely low-grade:
      • Grade 3-4 TRAEs occurred in 17-27% of patients.
      • VEGF inhibition-related side effects were manageable, with most being ≤ grade 3.
    • A single treatment discontinuation occurred, attributed to TRAE, in the dose-escalation group.
  • Pharmacokinetics: MK-2010 demonstrated favorable pharmacokinetics, with an average half-life of 9.5-12.6 days.
  • MK-2010 is demonstrating early signs of clinical efficacy and a manageable safety profile in NSCLC patients, including heavily pretreated individuals. The 55% ORR in first-line NSCLC patients at the 20 mg/kg Q3W dose and low occurrence of grade ≥3 TRAEs (17%) highlight its potential as both monotherapy and in combination settings.

Akeso (9926.HK) Presents Promising Phase II Data for Cadonilimab Combination in Locally Advanced Pancreatic Cancer at AACR 2026

Key Words: Akeso, Cadonilimab, PD-1/CTLA-4 bispecific antibody, Pancreatic Cancer, COMPASSION-26, AACR 2026

• The News: Akeso announced positive Phase II results from the COMPASSION-26 study, evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, in combination with chemotherapy as a first-line treatment for advanced pancreatic ductal adenocarcinoma (PDAC). The data were presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting.
• Key Highlights:
• In patients with locally advanced pancreatic cancer, the combination demonstrated:
  • Median progression-free survival (PFS): 11.1 months.
  • Median overall survival (OS): Exceeded 23 months.
  • 12-month OS rate: 91.7%.
  • 24-month OS rate: 44.1%.
• Across the study population, the regimen showed:
  • Objective response rate (ORR): 33.9%.
  • Disease control rate (DCR): 96.4%.
• Safety and Tolerability:
  • The safety profile of cadonilimab plus chemotherapy was favorable and manageable.
  • No new safety signals were observed.
  • Grade 3-4 treatment-related adverse events (TRAEs) occurred at a low rate of 17-27%, with no treatment-related deaths.

Prepared by the Selesta Research Team.

research@selesta.ai

Selesta is a healthcare and life science advisory firm dedicated to serving Asia’s emerging entrepreneurs and businesses.

DISCLAIMER

This document is prepared by Selesta Partners Limited (“Selesta”) for information purposes only.  Neither Selesta nor the Directors of the company accept any responsibility whatsoever for the accuracy or completeness of the information provided by third parties contained in this document. It should not be copied or distributed to third parties without the written consent of Selesta.

The views expressed (if any) are the views of Selesta only and are subject to change based on market and other conditions. The information provided does not constitute investment advice and it should not be relied on as such. All material has been obtained from sources believed to be reliable at the date of presentation, but its accuracy is not guaranteed. This material contains certain statements that may be deemed forward-looking statements. Please note that any such statements are not guarantees of any future performance and actual results or developments may differ materially from those projected.

The information contained herein does not constitute an offer to sell or an invitation to buy any securities in any jurisdiction in which such distribution or offer is not authorized to any person. No part of this document, or any information contained herein, may be distributed, reproduced, taken or transmitted into jurisdiction or territories/ possession in which such activities are not permitted. Any failure to comply with the restrictions may constitute a violation of the relevant laws.

This document does not constitute a prospectus, an offer or an invitation to subscribe to any securities, or a recommendation in relation to any securities.

Investors should note investment involves risk and past performance is not indicative of future results.

© 2026 Selesta